In vivo, transgenic mouse data demonstrated that expression of LRRK2 G2019S exacerbates α-syn aggregation, dopaminergic neuron degeneration, as well as associated neuroinflammatory and behavioral impairments in a PFF-based mouse model of PD. This evidence concerns the gene LRRK2 and Parkinson disease.